The HER2 World: Better Treatment Selection for Better Outcome

Author： Tagliabue Elda   Campiglio Manuela   Pupa Serenella M.   Balsari Andrea   Mnard Sylvie  

Publisher： Oxford University Press

ISSN： 1052-6773

Source： Journal of the National Cancer Institute Monographs, Vol.2011, Iss.43, 2011-10, pp. : 82-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2 Blockade: Is Combination Therapy Better Than Monotherapy?

By Hirsh Rebecca  

Current Treatment Options in Oncology, Vol. 11, Iss. 3-4, 2010-12 ,pp. : 63-65

Springer Publishing Company

Access to resources Recommend Favorite

Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?

By Kurt Mevlut   Aksoy Sercan   Guler Nilufer  

Acta Oncologica, Vol. 45, Iss. 5, 2006-07 ,pp. : 625-626

Informa Healthcare

Access to resources Recommend Favorite

The earlier the better?

By Terashima Masanori  

Gastric Cancer, Vol. 17, Iss. 2, 2014-04 ,pp. : 197-199

Springer Publishing Company

Access to resources Recommend Favorite

Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis Brelated hepatocellular carcinoma following octreotide longacting release treatment

By      

Oncology Letters, Vol. 6, Iss. 3, 2013-01 ,pp. : 821-828

Spandidos Publications

Access to resources Recommend Favorite

Treatment strategy for HER2-positive breast cancer

By Mukai Hirofumi  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 335-340

Springer Publishing Company

Access to resources Recommend Favorite